COVID-19: Avigan, Okayama/ 4 Administration at medical institution: Confirmed improvement of symptoms
COVID-19: Avigan
Okayama: Conducting clinical trials
All four designated medical institutions in Okayama Prefecture are ready to use the therapeutic drug “Avigan” for new corona patients for research purposes.
It was discovered on April 14th by interviewing medical personnel.
Administration of the therapeutic drug “Avigan” to patients in the prefecture has already started, and symptoms have been confirmed to have improved thereafter.
Avigan:
Developed by FUJIFILM’s “FUJIFILM Toyama Chemical” (Tokyo), it is said to suppress the growth of new corona / RNA virus.
A clinical study in China reported that the patient’s condition had improved, and clinical trials for approval have started in Japan from the end of March.
All 4 designated medical institutions：
Okayama University Hospital (Okayama City),
Okayama Municipal Hospital (the same city),
Kurashiki Central Hospital (Kurashiki City),
Tsuyama Central Hospital (Tsuyama City).
According to medical personnel,
“In any case, it is possible to administer to a patient with the request of the individual and the approval of the ethics committee of the hospital.”
However, it has been pointed out that abigan may cause malformations in the fetus in animal experiments, and it cannot be used for pregnant women or women who may be pregnant.
Confirm symptom improvement:
When administered to a patient who needs a ventilator, “recovers the condition in which the ventilator can be removed within a few days.”
Doctors are investigating the correlation between treatment and symptom improvement.
Japanese government:
Over 120 patients were administered nationwide, and a certain therapeutic effect was confirmed.
If it is safe and effective, it may be used as a therapeutic drug after July.
The state has a policy to increase the stockpiling amount of Avigan to 3 times the present amount, up to 2 million minutes.
Sanyo Shimbun Digital
https://www.sanyonews.jp/sp/article/1003803
Is it a silver bullet for the new coronavirus? “Avigan” test progress | Chant! | CBC TV
Fujita Medical University Hospital
We are aiming to collect data for 86 people in collaboration with several hospitals nationwide,
Wait for the overall result to determine if it works.
Early March: This research
We divide patients who are asymptomatic or mild and have the consent of 16 years or older with the virus into two groups.
First, we administer Avigan to Group 1.
Second, the second group is initially not given Avigan.
Check if there is a difference in the amount of virus change in cells for 5 days.
And also pay attention to whether the fever period will be shorter.
Yohei Doi: Department of Infectious Diseases
At mild stage, “By taking Avigan, the virus load can be reduced early”
In other words, it’s easier to control things like clusters and overshoots.